Abstract
Diabetes caused a total annual cost of $548 billion worldwide in 2013 and accounted for 11% of total healthcare expenditures for adults. The aim of this study is to conduct a pharmacoeconomic evaluation of insulin glargine injection 300 Units/mL (IGI-300U/mL), used to treat type-1 and 2 diabetes (T1DM-T2DM), and compare its cost-minimization to that of its competitors in Turkiye.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
